About the Company
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.
Employees
15
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $OCGN News
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
Ocugen's Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon
Ophthalmology is on the crest of a wave; a paradigm shift heralded by Ocugen, Inc (NASDAQ: OCGN) may be imminent. The ...
Ocugen Names Qamar Chief Medical Officer
Ocugen, Inc. (OCGN) on Monday announced the appointment of Huma Qamar as its chief medical officer. Huma Qamar has previously served ...
Ocugen to Present at Investing in Cures Summit
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...
Ocugen (OCGN) Price Target Increased by 58.33% to 6.46
Ocugen Background Information (This description is provided by the company.) Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to ...
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...
Ocugen Clinical Showcase Webcast Now Available
MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
Ocugen completes dosing of subjects with geographic atrophy in Phase 1/2 clinical trial of OCU410
OCU410 is a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age related ...
Ocugen Inc OCGN
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Ocugen, Inc. (OCGN)
MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...
Ocugen, Inc. (OCGN)
MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
Loading the latest forecasts...